Heart regeneration with engineered myocardial tissue

Annual Review of Biomedical Engineering

Volumn 16, Issue , 2014, Pages 1-28

  Coulombe, Kareen L K ^a,b   Bajpai, Vivek K ^c   Andreadis, Stelios T ^a,c,d   Murry, Charles E ^a,b,e,f  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c the State University of New York   (United States)

^d University at Buffalo The State University of New York   (United States)

^e University of Washington   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cardiac tissue engineering; cardiovascular regenerative medicine; coronary artery disease; heart failure; microvessel engineering; myocardial infarction; stem cells

Indexed keywords

CARDIOLOGY; CELL CULTURE; CELL SIGNALING; DISEASES; ENDOTHELIAL CELLS; HEART; STEM CELLS; TISSUE REGENERATION;

CARDIAC TISSUE ENGINEERING; CORONARY ARTERY DISEASE; HEART FAILURE; MICROVESSEL; MYOCARDIAL INFARCTION; REGENERATIVE MEDICINE;

TISSUE;

GROWTH FACTOR; TISSUE SCAFFOLD;

ANGIOGENESIS; CELL COMMUNICATION; COCULTURE; ENDOTHELIUM CELL; HEART; HEART DISEASE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; NONHUMAN; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; STROMA CELL; TISSUE ENGINEERING; TISSUE REGENERATION; VASCULAR TISSUE; VASCULARIZATION; ANIMAL; CARDIAC MUSCLE; CELL LINEAGE; CYTOLOGY; FIBROBLAST; METABOLISM; MICROCIRCULATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROCEDURES; RAT; REGENERATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL COMMUNICATION; CELL LINEAGE; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; FIBROBLASTS; HEART; HEART DISEASES; HUMANS; MICE; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; PLURIPOTENT STEM CELLS; RATS; REGENERATION; STROMAL CELLS; TISSUE ENGINEERING;

EID: 84904284990     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071812-152344     Document Type: Review

References (186)

1. Laflamme MA, Murry CE. 2011. Heart regeneration. Nature 473:326-35
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-128
3. Murry CE, Reinecke H, Pabon LM. 2006. Regeneration gaps: observations on stem cells and cardiac repair. J. Am. Coll. Cardiol. 47:1777-85
4. Sacks MS, Schoen FJ, Mayer JE. 2009. Bioengineering challenges for heart valve tissue engineering. Annu. Rev. Biomed. Eng. 11:289-313
5. Adler CP, Friedburg H. 1986. Myocardial DNA content, ploidy level and cell number in geriatric hearts: post-mortem examinations of human myocardium in old age. J. Mol. Cell. Cardiol. 18:39-53
6. Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG. 1984. Exercise cardiac output is maintained with advancing age in healthy human subjects: Cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 69:203-13
7. Young AA, Cowan BR. 2012. Evaluation of left ventricular torsion by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 14:49
8. Ausoni S, Sartore S. 2009. The cardiovascular unit as a dynamic player in disease and regeneration. Trends Mol. Med. 15:543-52
9. Nees S, Weiss DR, Juchem G. 2013. Focus on cardiac pericytes. Pflügers Arch. 465:779-87
10. Kaneko N, Matsuda R, Toda M, Shimamoto K. 2011. Three-dimensional reconstruction of the human capillary network and the intramyocardial micronecrosis. Am. J. Physiol. Heart Circ. Physiol. 300:H754-61
11. Stratman AN, Davis GE. 2012. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc. Microanal. 18:68-80
12. Murry CE, Keller G. 2008. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132:661-80
13. Srivastava D. 2006. Making or breaking the heart: from lineage determination to morphogenesis. Cell 126:1037-48
14. Buckingham M, Meilhac S, Zaffran S. 2005. Building the mammalian heart from two sources of myocar-dial cells. Nat. Rev. Genet. 6:826-35
15. Perez-Pomares JM, de la Pompa JL. 2011. Signaling during epicardium and coronary vessel development. Circ. Res. 109:1429-42
16. Tian X, Hu T, Zhang H, He L, Huang X, et al. 2013. Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res. 23:1075-90
17. Cossette S, Misra R. 2011. The identification of different endothelial cell populations within the mouse proepicardium. Dev. Dyn. 240:2344-53
18. Tomanek RJ. 1996. Formation of the coronary vasculature: a brief review. Cardiovasc. Res. 31:E46-51
19. Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, et al. 2011. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8:228-40
20. Ye L, Zimmermann WH, Garry DJ, Zhang J. 2013. Patching the heart: cardiac repair from within and outside. Circ. Res. 113:922-32
21. Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A, Yau TM. 1999. Survival and function of bioengineered cardiac grafts. Circulation 100:II63-69
22. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, et al. 2007. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25:1015-24
23. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, et al. 2008. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453:524-28
24. Burridge PW, Keller G, Gold JD, Wu JC. 2012. Production of de novo cardiomyocytes: human pluripo-tent stem cell differentiation and direct reprogramming. Cell Stem Cell 10:16-28
25. Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry CE. 2010. Endogenous Wnt/β-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS ONE 5:e11134
26. Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, et al. 2007. Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc. Natl. Acad. Sci. USA 104:9685-90
27. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, et al. 2006. Developmental stage-specific biphasic roles of Wnt/β-catenin signaling in cardiomyogenesis and hematopoiesis. Proc. Natl. Acad. Sci. USA 103:19812-17
28. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, et al. 2012. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. USA 109:E1848-57
29. Kim C, Majdi M, Xia P, Wei KA, Talantova M, et al. 2010. Non-cardiomyocytes influence the electro-physiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev. 19:783-95
30. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, et al. 2011. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 29:1011-18
31. Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, et al. 2011. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS ONE 6:e23657
32. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, et al. 2010. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat. Methods 7:61-66
33. Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, et al. 2013. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12:127-37
34. Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Murry CE. 2010. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J. Mol. Cell. Cardiol. 49:941-49
35. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, et al. 2012. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485:593-98
36. Song K, Nam YJ, Luo X, Qi X, Tan W, et al. 2012. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485:599-604
37. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, et al. 2012. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ. Res. 111:50-55
38. Addis RC, Epstein JA. 2013. Induced regeneration-the progress and promise of direct reprogramming for heart repair. Nat. Med. 19:829-36
39. Wang L, Li L, Shojaei F, Levac K, Cerdan C, et al. 2004. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 21:31-41
40. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. 2007. Development of the heman-gioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 109:2679-87
41. White MP, Rufaihah AJ, Liu L, Ghebremariam YT, Ivey KN, et al. 2013. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells 31:92-103
42. Li Z, Wilson KD, Smith B, Kraft DL, Jia F, et al. 2009. Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction. PLoS ONE 4:e8443
43. Nourse MB, Halpin DE, Scatena M, Mortisen DJ, Tulloch NL, et al. 2010. VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering. Arterioscler. Thromb. Vasc. Biol. 30:80-89
44. Kane NM, Meloni M, Spencer HL, Craig MA, Strehl R, et al. 2010. Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 30:1389-97
45. Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, et al. 2013. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev. Cell 26:204-19
46. Kreutziger KL, Muskheli V, Johnson P, Braun K, Wight TN, Murry CE. 2011. Developing vasculature and stroma in engineered human myocardium. Tissue Eng. Part A 17:1219-28
47. Stevens KR, Kreutziger KL, Dupras SK, Korte FS, Regnier M, et al. 2009. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc. Natl. Acad. Sci. USA 106:16568-73
48. Caspi O, Lesman A, Basevitch Y, Gepstein A, Arbel G, et al. 2007. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ. Res. 100:263-72
49. Vrancken Peeters MPFM, Gittenberger-de Groot AC, Mentink MMT, Poelmann RE. 1999. Smooth muscle cells and fibroblasts of the coronary arteries derive from epithelial-mesenchymal transformation of the epicardium. Anat. Embryol. 199:367-78
50. Descamps B, Emanueli C. 2012. Vascular differentiation from embryonic stem cells: novel technologies and therapeutic promises. Vasc. Pharmacol. 56:267-79
51. Cheung C, Sinha S. 2011. Human embryonic stem cell-derived vascular smooth muscle cells in therapeutic neovascularisation. J. Mol. Cell. Cardiol. 51:651-64
52. Bajpai VK, Mistriotis P, Loh YH, Daley GQ, Andreadis ST. 2012. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. Cardiovasc. Res. 96:391-400
53. El-Mounayri O, Mihic A, Shikatani EA, Gagliardi M, Steinbach SK, et al. 2013. Serum-free differentiation of functional human coronary-like vascular smooth muscle cells from embryonic stem cells. Cardiovasc. Res. 98:125-35
54. Cheung C, Bernardo AS, Trotter MW, Pedersen RA, Sinha S. 2012. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat. Biotechnol. 30:165-73
55. Paul JD, Coulombe KL, Toth PT, Zhang Y, Marsboom G, et al. 2013. SLIT3-ROBO4 activation promotes vascular network formation in human engineered tissue and angiogenesis in vivo. J. Mol. Cell. Cardiol. 64:124-31
56. Zeisberg EM, Kalluri R. 2010. Origins of cardiac fibroblasts. Circ. Res. 107:1304-12
57. Leask A. 2010. Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 106:1675-80
58. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. 2009. Origin of cardiac fibroblasts and the role of periostin. Circ. Res. 105:934-47
59. Challa AA, Vukmirovic M, Blackmon J, Stefanovic B. 2012. Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. PLoS ONE 7:e42989
60. Cotton JM, Kearney MT, MacCarthy PA, Grocott-Mason RM, McClean DR, et al. 2001. Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 104:2318-23
61. Paulus WJ, Vantrimpont PJ, Shah AM. 1995. Paracrine coronary endothelial control of left ventricular function in humans. Circulation 92:2119-26
62. Mohan P, Brutsaert DL, Sys SU. 1995. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins. Cardiovasc. Res. 29:637-40
63. Dostal DE, Baker KM. 1999. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ. Res. 85:643-50
64. Meulemans AL, Andries LJ, Brutsaert DL. 1990. Does endocardial endothelium mediate positive in-otropic response to angiotensin I and angiotensin II? Circ. Res. 66:1591-601
65. Chua BH, Chua CC, Diglio CA, Siu BB. 1993. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta 1178:201-6
66. Kusaka Y, Kelly RA, Williams GH, Kifor I. 2000. Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway. Am. J. Physiol. Heart Circ. Physiol. 279:H1087-96
67. McClellan G, Weisberg A, Rose D, Winegrad S. 1994. Endothelial cell storage and release of endothelin as a cardioregulatory mechanism. Circ. Res. 75:85-96
68. Li K, Stewart DJ, Rouleau JL. 1991. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles: role of endocardial endothelium. Circ. Res. 69:301-12
69. Drawnel FM, Archer CR, Roderick HL. 2013. The roleof the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br. J. Pharmacol. 168:296-317
70. Kakkar R, Lee RT. 2009. Intramyocardial fibroblast myocyte communication. Circ. Res. 106:47-57
71. Zhang Y, Kanter EM, Laing JG, Aprhys C, Johns DC, et al. 2008. Connexin43 expression levels influence intercellular coupling and cell proliferation of native murine cardiac fibroblasts. Cell Commun. Adhes. 15:289-303
72. Hilenski LL, Terracio L, Borg TK. 1991. Myofibrillar and cytoskeletal assembly in neonatal rat cardiac myocytes cultured on laminin and collagen. Cell Tissue Res. 264:577-87
73. Li YY, McTiernan CF, Feldman AM. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res. 46:214-24
74. Vlodavsky I, Fuks Z, Ishai-Michaeli R, Bashkin P, Levi E, et al. 1991. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J. Cell. Biochem. 45:167-76
75. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. 2005. Neuregulin-1αand βisoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp. Cell Res. 311:135-46
76. Cote GM, Sawyer DB, Chabner BA. 2012. ERBB2 inhibition and heart failure. N. Engl. J. Med. 367:2150-53
77. Kreutziger KL, Murry CE. 2011. Engineered human cardiac tissue. Pediatr. Cardiol. 32:334-41
78. Thompson JA, Anderson KD, DiPietro JM, Zwiebel JA, Zametta M, et al. 1988. Site-directed neovessel formation in vivo. Science 241:1349-52
79. Wake MC, Patrick CW Jr, Mikos AG. 1994. Pore morphology effects on the fibrovascular tissue growth in porous polymer substrates. Cell Transplant. 3:339-43
80. Mikos AG, Sarakinos G, Lyman MD, Ingber DE, Vacanti JP, Langer R. 1993. Prevascularization of porous biodegradable polymers. Biotechnol. Bioeng. 42:716-23
81. Peters MC, Polverini PJ, Mooney DJ. 2002. Engineering vascular networks in porous polymer matrices. J. Biomed. Mater. Res. 60:668-78
82. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. 2001. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 33:907-21
83. Muschler GF, Nakamoto C, Griffith LG. 2004. Engineering principles of clinical cell-based tissue engineering. J. Bone Joint Surg. Am. 86:1541-58
84. Giraud MN, Armbruster C, Carrel T, Tevaearai HT. 2007. Current state of the art in myocardial tissue engineering. Tissue Eng. 13:1825-36
85. Pessanha MG, Mandarim-de-Lacerda CA. 2000. Influence of the chronic nitric oxidesynthesis inhibition on cardiomyocytes number. Virchows Arch. 437:667-74
86. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, et al. 2007. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204:3037-47
87. Trial J, Rossen RD, Rubio J, Knowlton AA. 2004. Inflammation and ischemia: Macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp. Biol. Med. (Maywood) 229:538-45
88. Troidl C, Möllmann H, Nef H, Masseli F, Voss S, et al. 2009. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J. Cell. Mol. Med. 13:3485-96
89. Freytes DO, Santambrogio L, Vunjak-Novakovic G. 2012. Optimizing dynamic interactions between a cardiac patch and inflammatory host cells. Cells Tissues Organs 195:171-82
90. Robey TE, Saiget MK, Reinecke H, Murry CE. 2008. Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell. Cardiol. 45:567-81
91. Nakamura Y, Yasuda T, Weisel RD, Li RK. 2006. Enhanced cell transplantation: Preventing apoptosis increases cell survival and ventricular function. Am. J. Physiol. Heart Circ. Physiol. 291:H939-47
92. Weyers JJ, Schwartz SM, Minami E, Carlson DD, Dupras SK, et al. 2013. Effects of cell grafting on coronary remodeling after myocardial infarction. J. Am. Heart Assoc. 2:e000202
93. Cassell OC, Hofer SO, Morrison WA, Knight KR. 2002. Vascularisation of tissue-engineered grafts: the regulation of angiogenesis in reconstructive surgery and in disease states. Br. J. Plast. Surg. 55:603-10
94. Arkudas A, Tjiawi J, Saumweber A, Beier JP, Polykandriotis E, et al. 2009. Evaluation of blood vessel ingrowth in fibrin gel subject to type and concentration of growth factors. J. Cell. Mol. Med. 13:2864-74
95. Liu ZC, Chang TM. 2010. Artificial cell microencapsulated stem cells in regenerative medicine, tissue engineering and cell therapy. Adv. Exp. Med. Biol. 670:68-79
96. Saxena AK, Marler J, Benvenuto M, Willital GH, Vacanti JP. 1999. Skeletal muscle tissue engineering using isolated myoblasts on synthetic biodegradable polymers: preliminary studies. Tissue Eng. 5:525-32
97. Dvir T, Kedem A, Ruvinov E, Levy O, Freeman I, et al. 2009. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc. Natl. Acad. Sci. USA 106:14990-95
98. Laschke MW, Rucker M, Jensen G, Carvalho C, Mulhaupt R, et al. 2008. Improvement of vascular-ization of PLGA scaffolds by inosculation of in situ-preformed functional blood vessels with the host microvasculature. Ann. Surg. 248:939-48
99. Amir G, Miller L, Shachar M, Feinberg MS, Holbova R, et al. 2009. Evaluation of a peritoneal-generated cardiac patch in a rat model of heterotopic heart transplantation. Cell Transplant. 18:275-82
100. Erol OO, Spira M. 1979. New capillary bed formation with a surgically constructed arteriovenous fistula. Surg. Forum 30:530-31
101. Khouri RK, Upton J, Shaw WW. 1991. Prefabrication of composite free flaps through staged microvas-cular transfer: an experimental and clinical study. Plast. Reconstr. Surg. 87:108-15
102. Morrison WA, Penington AJ, Kumta SK, Callan P. 1997. Clinical applications and technical limitations of prefabricated flaps. Plast. Reconstr. Surg. 99:378-85
103. Tanaka Y, Sung KC, Tsutsumi A, Ohba S, Ueda K, Morrison WA. 2003. Tissue engineering skin flaps: Which vascular carrier, arteriovenous shunt loop or arteriovenous bundle, has more potential for angiogenesis and tissue generation? Plast. Reconstr. Surg. 112:1636-44
104. Warnke PH, Springer IN, Wiltfang J, Acil Y, Eufinger H, et al. 2004. Growth and transplantation of a custom vascularised bone graft in a man. Lancet 364:766-70
105. Lokmic Z, Stillaert F, Morrison WA, Thompson EW, Mitchell GM. 2007. An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct. FASEB J. 21:511-22
106. Mian R, Morrison WA, Hurley JV, Penington AJ, Romeo R, et al. 2000. Formation of new tissue from an arteriovenous loop in the absence of added extracellular matrix. Tissue Eng. 6:595-603
107. Tanaka Y, Tsutsumi A, Crowe DM, Tajima S, Morrison WA. 2000. Generation of an autologous tissue (matrix) flap by combining an arteriovenous shunt loop with artificial skin in rats: preliminary report. Br. J. Plast. Surg. 53:51-57
108. Lokmic Z, Thomas JL, Morrison WA, Thompson EW, Mitchell GM. 2008. An endogenously deposited fibrin scaffold determines construct size in the surgically created arteriovenous loop chamber model of tissue engineering. J. Vasc. Surg. 48:974-85
109. Cassell OC, Morrison WA, Messina A, Penington AJ, Thompson EW, et al. 2001. The influence of extracellular matrix on the generation of vascularized, engineered, transplantable tissue. Ann. N.Y. Acad. Sci. 944:429-42
110. Rophael JA, Craft RO, Palmer JA, Hussey AJ, Thomas GP, et al. 2007. Angiogenic growth factor syner-gism in a murine tissue engineering model of angiogenesis and adipogenesis. Am. J. Pathol. 171:2048-57
111. Arkudas A, Tjiawi J, Bleiziffer O, Grabinger L, Polykandriotis E, et al. 2007. Fibrin gel-immobilized VEGF and bFGF efficiently stimulate angiogenesis in the AV loop model. Mol. Med. 13:480-87
112. Morritt AN, Bortolotto SK, Dilley RJ, Han X, Kompa AR, et al. 2007. Cardiac tissue engineering in an in vivo vascularized chamber. Circulation 115:353-60
113. Birla RK, Borschel GH, Dennis RG, Brown DL. 2005. Myocardial engineering in vivo: formation and characterization of contractile, vascularized three-dimensional cardiac tissue. Tissue Eng. 11:803-13
114. Polykandriotis E, Horch RE, Arkudas A, Labanaris A, Brune K, et al. 2006. Intrinsic versus extrinsic vascularization in tissue engineering. Adv. Exp. Med. Biol. 585:311-26
115. Arkudas A, Pryymachuk G, Beier JP, Weigel L, Korner C, et al. 2012. Combination of extrinsic and intrinsic pathways significantly accelerates axial vascularization of bioartificial tissues. Plast. Reconstr. Surg. 129:55e-65e
116. Folkman J, Haudenschild C. 1980. Angiogenesis in vitro. Nature 288:551-56
117. Montesano R, Orci L, Vassalli P. 1983. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J. Cell Biol. 97:1648-52
118. Vernon RB, Angello JC, Iruela-Arispe ML, Lane TF, Sage EH. 1992. Reorganization of basement membrane matrices bycellular traction promotes the formationofcellular networksin vitro.Lab. Investig. 66:536-47
119. Ilan N, Mahooti S, Madri JA. 1998. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci. 111:3621-31
120. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, et al. 2001. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab. Investig. 81:453-63
121. Orlidge A, D'Amore PA. 1987. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell Biol. 105:1455-62
122. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. 2004. Tissue engineering: creation of long-lasting blood vessels. Nature 428:138-39
123. Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, et al. 2000. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc. Natl. Acad. Sci. USA 97:9191-96
124. Black AF, Berthod F, L'Heureux N, Germain L, Auger FA. 1998. In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. FASEB J. 12:1331-40
125. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. 2004. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration.Circulation 110:962-68
126. Sekine H, Shimizu T, Hobo K, Sekiya S, Yang J, et al. 2008. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation 118:S145-52
127. Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, et al. 2005. Engineering vascularized skeletal muscle tissue. Nat. Biotechnol. 23:879-84
128. Chang EI, Bonillas RG, El-ftesi S, Ceradini DJ, Vial IN, et al. 2009. Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds. FASEB J. 23:906-15
129. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, et al. 2008. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 14:213-21
130. Frame MD, Sarelius IH. 1995. A system for culture of endothelial cells in 20-50-μm branching tubes. Microcirculation 2:377-85
131. Kaihara S, Borenstein J, Koka R, Lalan S, Ochoa ER, et al. 2000. Silicon micromachining to tissue engineer branched vascular channels for liver fabrication. Tissue Eng. 6:105-17
132. Neumann T, Nicholson BS, Sanders JE. 2003. Tissue engineering of perfused microvessels. Microvasc. Res. 66:59-67
133. Ko IK, Iwata H. 2001. An approach to constructing three-dimensional tissue. Ann. N.Y. Acad. Sci. 944:443-55
134. Golden AP, Tien J. 2007. Fabrication of microfluidic hydrogels using molded gelatin as a sacrificial element. Lab Chip 7:720-25
135. Choi NW, Cabodi M, Held B, Gleghorn JP, Bonassar LJ, Stroock AD. 2007. Microfluidic scaffolds for tissue engineering. Nat. Mater. 6:908-15
136. Zheng Y, Chen J, Craven M, Choi NW, Totorica S, et al. 2012. In vitro microvessels for the study of angiogenesis and thrombosis. Proc. Natl. Acad. Sci. USA 109:9342-47
137. Yang S, Leong KF, Du Z, Chua CK. 2001. The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Eng. 7:679-89
138. Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, et al. 2010. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc. Natl. Acad. Sci. USA 107:15211-16
139. Radisic M, Park H, Chen F, Salazar-Lazzaro JE, Wang Y, et al. 2006. Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. Tissue Eng. 12:2077-91
140. Druecke D, Langer S, Lamme E, Pieper J, Ugarkovic M, et al. 2004. Neovascularization of poly(ether ester) block-copolymer scaffoldsinvivo: long-term investigations using intravitalfluorescent microscopy. J. Biomed. Mater. Res. A 68:10-18
141. Hollister SJ. 2005. Porous scaffold design for tissue engineering. Nat. Mater. 4:518-24
142. Billiet T, Vandenhaute M, Schelfhout J, Van Vlierberghe S, Dubruel P. 2012. A review of trends and limitations in hydrogel-rapid prototyping for tissue engineering. Biomaterials 33:6020-41
143. Cui X, Boland T. 2009. Human microvasculature fabrication using thermal inkjet printing technology. Biomaterials 30:6221-27
144. Testa U, Pannitteri G, Condorelli GL. 2008. Vascular endothelial growth factors in cardiovascular medicine. J. Cardiovasc. Med. (Hagerstown) 9:1190-221
145. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-48
146. Gurdon JB, Bourillot PY. 2001. Morphogen gradient interpretation. Nature 413:797-803
147. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, et al. 2004. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Investig. 113:516-27
148. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. 2001. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc. Res. 49:532-42
149. Post MJ, Laham R, Sellke FW, Simons M. 2001. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 49:522-31
150. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, et al. 2002. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124:28-34
151. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161:1163-77
152. Helm CL, Fleury ME, Zisch AH, Boschetti F, Swartz MA. 2005. Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc. Natl. Acad. Sci. USA 102:15779-84
153. Yang J, Zhou W, Zheng W, Ma Y, Lin L, et al. 2007. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107:17-29
154. Ye L, Haider H, Tan R, Su L, Law PK, et al. 2008. Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials 29:2125-37
155. Yau TM, Fung K, Weisel RD, Fujii T, Mickle DA, Li RK. 2001. Enhanced myocardial angiogenesis by gene transfer with transplanted cells. Circulation 104:I218-22
156. Richardson TP, Peters MC, Ennett AB, Mooney DJ. 2001. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19:1029-34
157. Yau TM, Kim C, Li G, Zhang Y, Fazel S, et al. 2007. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann. Thorac. Surg. 83:1110-19
158. Lee K, Silva EA, Mooney DJ. 2011. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface 8:153-70
159. Zisch AH, Lutolf MP, Hubbell JA. 2003. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc. Pathol. 12:295-310
160. Lutolf MP, Hubbell JA. 2005. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23:47-55
161. Geer DJ, Swartz DD, Andreadis ST. 2005. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am. J. Pathol. 167:1575-86
162. Liang MS, Andreadis ST. 2011. Engineering fibrin-binding TGF-β1 for sustained signaling and contractile function of MSC based vascular constructs. Biomaterials 32:8684-93
163. Murphy WL, Peters MC, Kohn DH, Mooney DJ. 2000. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 21:2521-27
164. Lee KY, Peters MC, Anderson KW, Mooney DJ. 2000. Controlled growth factor release from synthetic extracellular matrices. Nature 408:998-1000
165. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. 2003. Enhancing the vascularization of three-dimensional porous alginate scaffoldsby incorporating controlled release basic fibroblast growth factor microspheres. J. Biomed. Mater. Res. A 65:489-97
166. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, et al. 2007. Integrated approach to designing growth factor delivery systems. FASEB J. 21:3896-903
167. DeLong SA, Moon JJ, West JL. 2005. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 26:3227-34
168. Burdick JA, Khademhosseini A, Langer R. 2004. Fabrication of gradient hydrogels using a microflu-idics/photopolymerization process. Langmuir 20:5153-56
169. Borselli C, Oliviero O, Battista S, Ambrosio L, Netti PA. 2007. Induction of directional sprouting angiogenesis by matrix gradients. J. Biomed. Mater. Res. A 80:297-305
170. Liang MS, Koobatian M, Lei P, Swartz DD, Andreadis ST. 2013. Differential and synergistic effects of mechanical stimulation and growth factor presentationon vascular wall function. Biomaterials 34:7281-91
171. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, et al. 2003. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cellinvasion characteristics. Proc. Natl. Acad. Sci. USA 100:5413-18
172. Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, et al. 2003. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 17:2260-62
173. Phelps EA, Landazuri N, Thule PM, Taylor WR, Garcia AJ. 2010. Bioartificial matrices for therapeutic vascularization. Proc. Natl. Acad. Sci. USA 107:3323-28
174. Gospodarowicz D, Cheng J. 1986. Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128:475-84
175. Sommer A, Rifkin DB. 1989. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell. Physiol. 138:215-20
176. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I. 1989. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-43
177. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, et al. 2002. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16:2684-98
178. Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, et al. 2000. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J. Control. Release 64:103-14
179. Cai S, Liu Y, Zheng Shu X, Prestwich GD. 2005. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26:6054-67
180. Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, et al. 2006. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27:5242-51
181. Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, Van Kuppevelt TH. 2007. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 28:1123-31
182. Al-Lamki RS, Bradley JR, Pober JS. 2008. Endothelial cells in allograft rejection. Transplantation 86:1340-48
183. Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, et al. 2013. HLA engineering of human pluripotent stem cells. Mol. Ther. 21:1232-41
184. Parent AV, Russ HA, Khan IS, Laflam TN, Metzger TC, et al. 2013. Generation of functional thymic epithelium from human embryonic stem cells that supports host T cell development. Cell Stem Cell 13:219-29
185. Sun X, Xu J, Lu H, Liu W, Miao Z, et al. 2013. Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-like cells reconstitutes the thymic microenvironment in vivo. Cell Stem Cell 13:230-36
186. Laflamme MA, Zbinden S, Epstein SE, Murry CE. 2007. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu. Rev. Pathol. 2:307-39